文献速递肾小球疾病

重组Ig超家族补体受体预防致死性C3肾小球病

Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.
PubMed 文献 · J Am Soc Nephrol · 2018-06-12

C3肾小球病(C3G)由旁路补体途径(AP)失调引起,缺乏特异疗法。本研究在FHm/mP-/-致死性C3G小鼠模型中测试CRIg-Fc融合蛋白,发现其抑制AP激活、减少补体消耗,并显著改善生存率、蛋白尿、血尿、BUN及肾脏病理。结论提示基于可溶性CRIg机制的疗法可能对C3G有效,值得临床探索。

要点

  • CRIg-Fc通过结合C3b抑制AP的C3和C5转化酶。
  • 在FHm/mP-/-小鼠中,CRIg-Fc改善生存率并减轻肾脏损伤指标。
  • 该策略为C3G提供了非抗C5的新治疗方向。

核心结论

  • 基于可溶性CRIg作用机制开发的疗法可能对C3G有效,应进行临床探索。

研究设计与样本

  • 使用FHm/mP-/-小鼠(因子H和备解素基因突变)作为致死性C3G模型,测试CRIg-Fc融合蛋白与对照IgG的疗效。

主要发现

  • CRIg-Fc治疗抑制AP激活,减少血浆C3、因子B和C5消耗。
  • CRIg-Fc治疗组生存率显著改善,蛋白尿、血尿、BUN、肾小球C3片段、C9和纤维蛋白沉积及GN病理评分均降低。

临床怎么用

  • CRIg-Fc可能作为C3G的潜在靶向治疗,需进一步临床研究验证。

局限性

  • 研究仅基于小鼠模型,尚未在人体中验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background C3 glomerulopathy (C3G) is a life-threatening kidney disease caused by dysregulation of the alternative pathway of complement (AP) activation. No approved specific therapy is available for C3G, although an anti-C5 mAb has been used off-label in some patients with C3G, with mixed results. Thus, there is an unmet medical need to develop other inhibitors of complement for C3G.Methods We used a murine model of lethal C3G to test the potential efficacy of an Fc fusion protein of complement receptor of the Ig superfamily (CRIg-Fc) in the treatment of C3G. CRIg-Fc binds C3b and inhibits C3 and C5 convertases of the AP. Mice with mutations in the factor H and properdin genes (FHm/mP-/-) develop early-onset C3G, with AP consumption, high proteinuria, and lethal crescentic GN.Results Treatment of FHm/mP-/- mice with CRIg-Fc, but not a control IgG, inhibited AP activation and diminished the consumption of plasma C3, factor B, and C5. CRIg-Fc-treated FHm/mP-/- mice also had significantly improved survival and reduced proteinuria, hematuria, BUN, glomerular C3 fragment, C9 and fibrin deposition, and GN pathology scores.Conclusions Therapeutics developed on the basis of the mechanism of action of soluble CRIg may be effective for the treatment of C3G and should be explored clinically.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Wang X, Van Lookeren Campagne M, Katschke KJ, et al. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily. J Am Soc Nephrol. 2018. PMID: 29895552. doi:10.1681/ASN.2018030270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。